Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

U.S. awards contracts for bird flu vaccine

January 22, 2007 | A version of this story appeared in Volume 85, Issue 4

The Department of Health & Human Services has awarded contracts totaling $132.5 million to three vaccine makers for the development of bird flu vaccines using an immune system booster, or adjuvant. HHS awarded five-year contracts to GlaxoSmithKline for $63.3 million and Novartis for $54.8 million. In addition, Iomai will receive $14.4 million, plus possible additional funding, to develop a vaccine patch. "In the event of an influenza pandemic, a vaccine that uses an adjuvant could provide a way to extend a limited vaccine supply," says HHS Secretary Michael O. Leavitt.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.